NYSEARCA:PLX - NYSE Arca - US74365A3095 - Common Stock - Currency: USD
A fundamental and technical analysis of (NYSEARCA:PLX): PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) may be suited for high growth investing, we'll explore why in this article.
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.
Mentions: PFE
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
It's time for another dive into the biggest pre-market stock movers as we see what shares are on rising and falling on Tuesday!